As the country is still calculating the tally of the vaccine stock and medicines stolen in last week’s unrest in KwaZulu-Natal and Gauteng, there is still a lot of uncertainty about plans to restore medicine security.
The new and more contagious Delta variant has now surpassed the Beta variant to become the dominant SARS-CoV-2 variant in South Africa. Laura Lopez Gonzalez pulled together answers to eight common questions asked about this new variant.
The two vaccines used in South Africa’s vaccination programme, those from Johnson & Johnson and Pfizer/BioNTech, have both been shown to be highly effective against COVID-19, particularly in preventing hospitalisation and death. But protection may wane over time and new variants may or may not render these vaccines less effective. Adele Baleta unpacks what we do and do not know about the potential need for booster shots and surveys some of the studies that will help fill the gaps.
On Monday President Cyril Ramaphosa announced that South Africa will host the first World Health Organization-backed COVID-19 mRNA vaccine Technology Transfer Hub – an initiative designed to get the production of mRNA vaccines off the ground in Africa. Parties involved in the hub expect to hear as early as next week whether pharmaceutical companies with mRNA COVID-vaccines for COVID-19 on the market – Moderna and Pfizer/BioNTech – will share their know-how with the hub. Chris Bateman reports for Spotlight.
Government has been criticised for the slow pace of the country’s vaccine rollout which started on 17 May 2021. Elri Voigt spoke to experts to hear what is being done right in this vaccine rollout and where improvements are needed.
While it is uncertain when teachers in the Free State will receive vaccinations during this third wave, the number of COVID-19 infections and deaths in the province’s schools continues to increase. Refilwe Mochoari reports.
An experimental COVID-19 vaccine currently in Phase I trials being run by the University of Cape Town has a unique design that might allow it to offer better protection against current and future variants of the SARS-CoV-2 virus. Elri Voigt provides an update on the trial and unpacks the science behind this vaccine candidate.